Nigeria is charting a bold path to transform its pharmaceutical sector, targeting a 15% market share across Africa by 2030. This ambition is being driven by the Presidential Initiative to Unlock the Healthcare Value Chain (PVAC), a program established by President Bola Ahmed Tinubu in October 2023.
Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, shared the country’s vision, emphasizing the government’s resolve to reduce import dependency and create a self-sufficient healthcare ecosystem. “President Tinubu’s administration is focused on shifting Nigeria’s health sector from a consumption-driven model to one that generates jobs, boosts economic growth, and strengthens domestic manufacturing capacity,” Pate stated in a post on X (formerly Twitter).
A $1 Billion Lifeline for Local Healthcare Manufacturing
One of the cornerstone achievements of the PVAC initiative is a $1 billion memorandum of understanding (MoU) with the African Export-Import Bank (Afreximbank). This funding will provide critical support to domestic healthcare manufacturers and attract foreign investments into Nigeria’s burgeoning pharmaceutical industry.
“This is about building a robust healthcare system that ensures we meet domestic demands while remaining competitive globally,” Pate remarked. Over 70 new healthcare manufacturing companies have joined the initiative, with 22 large-scale projects already under active negotiation with international financiers.
Among the highlighted projects is a facility in Lagos producing active pharmaceutical ingredients (APIs), such as clavulanic acid. The project has already created over 700 jobs and is a step toward achieving Nigeria’s goal of meeting 70% of its pharmaceutical demand domestically by 2030.
Expanding Workforce and Building Infrastructure
The PVAC initiative seeks to double Nigeria’s life sciences manufacturing workforce, increasing it from approximately 20,000 to 50,000 full-time employees by 2030. The government also aims to establish at least two commercially viable vaccine production facilities and five medical manufacturing plants across the country.
Ongoing projects under the initiative include:
- A cryogenic air separation plant to produce medical oxygen.
- A rapid diagnostic kit manufacturing facility in collaboration with global firms.
- Agreements with Siemens Healthineers to set up an ultrasound assembly plant in Nigeria.
“These projects signal a shift in Nigeria’s healthcare narrative, creating opportunities for industrialization while addressing critical health needs,” Pate said.
Strengthening Local Industry with Global Partnerships
Nigeria is leveraging international partnerships to strengthen its healthcare value chain. For instance, the PVAC initiative has facilitated collaboration with South African firms to develop herbal diagnostic kits. Additionally, more than ten vertical value chains have been established to foster local production of essential healthcare commodities.
READ MORE: NCAA Chief Intervenes as Flight Delays, Cancellations Worsen During Festive Season
Prof. Pate underscored the importance of regulatory bodies such as the National Agency for Food and Drug Administration and Control (NAFDAC) and the Pharmacy Council of Nigeria in fostering a conducive environment for industry growth. “Strong regulations ensure our products meet global standards and help Nigeria remain competitive in international markets,” he added.
Transforming Healthcare Through Local Manufacturing
A significant focus of the PVAC initiative is reducing Nigeria’s reliance on imported healthcare commodities. Local manufacturing efforts now span vaccines, medical oxygen, diagnostic kits, and APIs, positioning Nigeria as a key player in Africa’s healthcare industry.
Prof. Pate highlighted the administration’s determination to achieve tangible outcomes: “For too long, we have depended on imports for even the most basic healthcare needs. This government is committed to industrialization, job creation, and economic growth, ensuring our healthcare sector becomes a hub for innovation and productivity.”
Economic and Social Impact
If successful, the PVAC initiative will not only position Nigeria as a pharmaceutical powerhouse but also provide significant economic and social benefits. By reducing import reliance, Nigeria could save billions of dollars annually and ensure a steady supply of life-saving medicines.
“This initiative is about securing a healthier future for Nigerians while making our economy more resilient,” Pate emphasized. He expressed optimism about the initiative’s progress, noting the government’s resolve to achieve its targets and deliver results that impact everyday lives.
The PVAC initiative is poised to not only enhance Nigeria’s healthcare sector but also create jobs, foster innovation, and position the country as a leading pharmaceutical producer in Africa by 2030.
